Brief: Calliditas Therapeutics - EMA Gives Positive Opinion On Application For Setanaxib
05/10/2023 11:11
Oct 5 (Reuters) - Calliditas Therapeutics AB CALTX.ST :
* EUROPEAN MEDICINES AGENCY COMMITTEE FOR ORPHAN MEDICINAL
PRODUCTS PROVIDES POSITIVE OPINION ON CALLIDITAS' APPLICATION
FOR SETANAXIB IN ALPORT SYNDROME
* COMP OPINION WILL NOW GO TO EUROPEAN COMMISSION
Source text for Eikon: ID:nWkr810x11
Further company coverage: CALTX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations